HCW Biologics Presents Newly Identified Distinctive Features of Its Lead T Cell Engager Candidate Built with Company’s Proprietary T-Cell Engager Platform, Further Supporting Its Use in Treating Solid Tumors at the Society for Immunotherapy of Cancer’s 41st Annual Meeting
HCW11-018b induces/promotes tertiary lymphoid structure formation inside tumors
Covered in this story
Call it yourself
No calls on $HCWB yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on HCW Biologics →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.